JATT II Acquisition, a blank check company targeting biotechs and life sciences businesses, raised $60 million by offering 6 million shares at $10. The company is not offering units with warrants or rights attached.
JATT II Acquisition is led by CEO and Chairman Someit Sidhu, who has founded and led several healthcare companies, most recently Khanda Therapeutics, where he serves as CEO. The SPAC plans to target healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences.
Sidhu's previous SPAC, JATT Acquisition, completed its combination with hair loss biotech Zura Bio (ZURA; -43% from $10 offer price) in 2023.
The Westfield, NJ-based company will trade on the Nasdaq under the symbol JATT. Guggenheim Securities acted as sole bookrunner on the deal.
